ライフサイエンスコーパス: pulmonary hemorrhage

1 osition, destruction of lung parenchyma, and pulmonary hemorrhage).

2 ratory failure caused by lung hypoplasia and pulmonary hemorrhage.

3 icities, including venoocclusive disease and pulmonary hemorrhage.

4 Only one patient had grade 3 pulmonary hemorrhage.

5 apy-plus-bevacizumab group, including 5 from pulmonary hemorrhage.

6 ed variables were evaluated as predictors of pulmonary hemorrhage.

7 e were used to develop a guinea pig model of pulmonary hemorrhage.

8 been isolated from the lung of a child with pulmonary hemorrhage.

9 There were six deaths from pulmonary hemorrhage.

10 , causing progressive glomerulonephritis and pulmonary hemorrhage.

11 severity of viral pneumonitis, and prevented pulmonary hemorrhage.

12 stinal hemorrhage, hemorrhagic cystitis, and pulmonary hemorrhage.

13 atient died shortly after BPA as a result of pulmonary hemorrhage.

14 ing an underlying mechanism for the observed pulmonary hemorrhage.

15 ith cutaneomucosal, cerebral, digestive, and pulmonary hemorrhages.

16 .3 [95% CI, 0.3 to 8.3]) and a lower rate of pulmonary hemorrhage (5.6% vs 8.9%; OR, 0.60 [95% CI, 0.

17 ized woman with known SLE who presented with pulmonary hemorrhage, acute renal failure, change in men

18 newborn who developed glomerulonephritis and pulmonary hemorrhage after transplacental transfer of an

19 Pulmonary hemorrhage after TTLB is common but rarely req

20 as controversially been linked to idiopathic pulmonary hemorrhage and "sick building syndrome." Howev

21 uction in the level of Foxf1 caused neonatal pulmonary hemorrhage and abnormalities in alveologenesis

22 itive microscopic polyangiitis, resulting in pulmonary hemorrhage and acute renal failure.

23 amination of patient 1 showed focal areas of pulmonary hemorrhage and diffuse alveolar damage, spleni

24 The recent increase in idiopathic pulmonary hemorrhage and hemosiderosis in young infants,

25 ciated with human health concerns, including pulmonary hemorrhage and hemosiderosis.

26 ung parasite burden together with aggravated pulmonary hemorrhage and higher alveolar total protein l

27 inflammatory vasculitides, which often cause pulmonary hemorrhage and infarction, result in florid bu

28 h severe respiratory failure with associated pulmonary hemorrhage and may be a life-sustaining suppor

29 condition of infants who present with acute pulmonary hemorrhage and respiratory failure.

30 e died immediately after birth due to severe pulmonary hemorrhage and structural defects in arterial

31 ate or severe hemorrhagic cystitis, 2.8% had pulmonary hemorrhage, and 2% had intracranial hemorrhage

32 times greater in patients who presented with pulmonary hemorrhage, and 3.78 (1.22, 11.70) times great

33 (14%) with hemorrhagic stroke, 77 (13%) with pulmonary hemorrhage, and 68 (12%) with hemorrhage assoc

34 nical findings included respiratory failure, pulmonary hemorrhage, and culture-negative septic shock.

35 Shp1 disruption leads to hyperinflammation, pulmonary hemorrhage, and increased mortality in both st

36 ematurity, duration of parenteral nutrition, pulmonary hemorrhage, and white matter injury (p<0.01 fo

37 -I release that promoted endothelial damage, pulmonary hemorrhages, and lung dysfunction.

38 m, also induced modest (25%) to severe (25%) pulmonary hemorrhage, another important feature of anti-

39 y and immune-related disorders causing acute pulmonary hemorrhage are reviewed.

40 prognostic indicators: (1) ANCA pattern; (2) pulmonary hemorrhage at onset; (3) presence of extrarena

41 ower in-hospital mortality and likelihood of pulmonary hemorrhage but not with differences in necroti

42 y copathogens, radiographic presentation, or pulmonary hemorrhage did not alter predictive values.

43 Primary outcomes were pulmonary hemorrhage, documented hemoptysis, and bleedin

44 enterocolitis (HR, 7.41; 95% CI, 5.14-10.7), pulmonary hemorrhage (HR, 10.0; 95% CI, 6.76-18.8), seve

45 events occurred in 4 cases (15%), including pulmonary hemorrhage, hypotension requiring vasoactive s

46 is, has previously been shown to cause fatal pulmonary hemorrhage in guinea pigs and asymptomatic chr

47 cause acute lethal infection with prominent pulmonary hemorrhage in guinea pigs.

48 ion of important clinical concepts regarding pulmonary hemorrhage in infants and children, recent rep

49 as demonstrated an association between acute pulmonary hemorrhage in infants and exposure to Stachybo

50 oimmune process may be the etiology of fatal pulmonary hemorrhage in leptospirosis.

51 The only complication was a self-limited pulmonary hemorrhage in one patient.

52 a cause of sudden death, despite evidence of pulmonary hemorrhage in one.

53 n mice produced hyperinflammation and lethal pulmonary hemorrhage in sterile inflammation and pathoge

54 Acute idiopathic pulmonary hemorrhage is a unique condition of infants wh

55 The hypothesis that acute idiopathic pulmonary hemorrhage is caused by toxigenic mold has not

56 ach to reducing the exposure of infants with pulmonary hemorrhage is suggested.

57 The etiology of pulmonary hemorrhage is unclear.

58 urther intraprocedure complications included pulmonary hemorrhage (n = 2), ventricular fibrillation (

59 th included respiratory distress or failure, pulmonary hemorrhage, necrotizing enterocolitis, catastr

60 Pulmonary hemorrhage occurred in 483 of the 1175 TTLBs (

61 Both were pulmonary hemorrhages, one occurring during treatment an

62 ed for mechanical ventilation support or had pulmonary hemorrhage or death.

63 arthritis and lung disease that presents as pulmonary hemorrhage or interstitial lung disease (ILD).

64 de therapy did not increase the incidence of pulmonary hemorrhage or other adverse events.

65 dysfunction (OR 1.89, 95% CI 1.17 to 3.03), pulmonary hemorrhage (OR 2.23, 95% CI 1.11 to 4.50), neu

66 Severe (grade >or= 3) pulmonary hemorrhage (PH) in advanced non-small-cell lun

67 Platelets simultaneously precluded lethal pulmonary hemorrhage resulting from fungal lung invasion

68 nd 1 patient with cholangiocarcinoma died of pulmonary hemorrhage secondary to a cavitating pulmonary

69 ry outcomes were major neonatal morbidities (pulmonary hemorrhage, severe bronchopulmonary dysplasia,

70 use strains was associated with jaundice and pulmonary hemorrhage, similar to the patient from whom t

71 nuing sorafenib, and one patient experienced pulmonary hemorrhage that was considered drug related.

72 The rate of fatal pulmonary hemorrhage was consistent with previous bevaci

73 Pulmonary hemorrhage was graded as follows: 0, none; 1,

74 The relative risk of pulmonary hemorrhage was no different by ANCA pattern.

75 Gross pulmonary hemorrhage was noted in most Abeta-infused ani

76 Areas of pulmonary hemorrhage were observed in bleomycin-treated

77 ospira acquired from patients suffering from pulmonary hemorrhage were used to develop a guinea pig m

78 n between squamous cell histology and severe pulmonary hemorrhage, whereas for pemetrexed, superior t

79 All patients had resolution of their pulmonary hemorrhage within 24 hrs.